Since the introduction of TNF blockers, several other biological agents have been approved for treating CD, including ustekinumab, which is a humanized monoclonal antibody that targets interleukin (IL)-12 and IL-23, and is one of the latest agents to be approved for use in moderate to severe CD [10]. The gene discussed is TNF; the disease is Cowden disease.